...
首页> 外文期刊>Arthritis care & research >Prevention of Acute Adverse Events Related to Infliximab Infusions in Pediatric Patients
【24h】

Prevention of Acute Adverse Events Related to Infliximab Infusions in Pediatric Patients

机译:预防与英夫利昔单抗输注相关的急性不良事件

获取原文
获取原文并翻译 | 示例
           

摘要

Objective. To study whether premedication with an oral antifebrile agent (acetaminophen) and antihistamine (cetirizine) could decrease the frequency of acute infusion reactions in pediatric patients.Methods. All pediatric patients scheduled for infliximab infusions at the Helsinki University Central Hospital, a tertiary care center, were prospectively introduced to a standard oral premedication of acetaminophen (20 mg/kg) and cetirizine (10 mg) prior to infliximab infusions for a period of 1 year. All acute adverse events related to infliximab infusions given according to the guidelines of pediatric rheumatologists or gastroenterologists were registered for this time period and retrospectively during the preceding year.Results. During the study period, infliximab infusions with premedication were given to 64 pediatric patients (48 with rheumatic disease and 16 with inflammatory bowel disease, mean age 13 years, n = 34 boys, and n = 30 girls). Infliximab was introduced to 14 children; the rest were on maintenance therapy. Twelve infusion reactions, 4 mild and 8 severe, were observed in 8 (12.5%) of the 64 subjects, and in 1 subject 4 times. During the preceding year, 60 pediatric patients had received infliximab infusions without premedication. In this latter group, infusion reactions occurred in 5 children (8.3%; P > 0.05). The presentation of an acute infusion reaction was not related to the sex or diagnosis of the patient. Conclusion. In pediatric patients, acute infusion reactions related to infliximab could not be prevented with premedication with oral acetaminophen and cetirizine.
机译:目的。研究口服抗发热剂(对乙酰氨基酚)和抗组胺药(西替利嗪)的前药治疗是否可以降低小儿患者急性输注反应的频率。在赫尔辛基大学中心医院(一家三级医疗中心)安排进行英夫利昔单抗输注的所有儿科患者,在接受英夫利昔单抗输注之前,均需接受对乙酰氨基酚(20 mg / kg)和西替利嗪(10 mg)的标准口服前药治疗。年。根据该小儿风湿病或肠胃病医生的指南给予的与英夫利昔单抗输注有关的所有急性不良事件均在该时间段内进行了登记,并在前一年进行了回顾。在研究期间,向64名儿科患者(其中风湿性疾病48例,炎性肠病16例,平均年龄13岁,n = 34个男孩,n = 30个女孩)进行了处方用英夫利昔单抗输注。英夫利昔单抗被引入14名儿童。其余的都是维持疗法。在64位受试者中有8位(12.5%)观察到十二次输液反应,分别为4次轻度和8次严重反应,在1位受试者中观察到4次。在前一年中,有60名儿科患者接受了英夫利昔单抗的输注,而没有进行药物治疗。在后一组中,有5名儿童发生了输液反应(8.3%; P> 0.05)。急性输注反应的表现与患者的性别或诊断无关。结论。在儿科患者中,口服对乙酰氨基酚和西替利嗪的预防性用药无法预防与英夫利昔单抗有关的急性输注反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号